Last reviewed · How we verify
Chelen (ETHYL CHLORIDE)
Ethyl chloride works by blocking sodium channels in nerve cells, preventing the transmission of pain signals to the brain.
Ethyl chloride, also known as Chelen, is a small molecule drug in the ethyl chloride class used for local anesthesia. It is not clear who originally developed the compound, but its current status is not publicly available. Chelen is approved for use in local anesthesia, but its commercial status and other details are unknown. As a local anesthetic, it works by numbing the area where it is applied, preventing pain signals from being transmitted to the brain. Further information on its development, approval, and safety is not available.
At a glance
| Generic name | ETHYL CHLORIDE |
|---|---|
| Drug class | ethyl chloride |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | discontinued |
Mechanism of action
When applied to the skin, ethyl chloride quickly numbs the area by blocking the sodium channels in nerve cells. This prevents the nerve cells from sending pain signals to the brain, making the area feel numb and pain-free. This effect is temporary and wears off once the ethyl chloride is metabolized and eliminated from the body.
Approved indications
- Local anesthesia
Common side effects
Key clinical trials
- Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (PHASE1,PHASE2)
- Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma (PHASE1,PHASE2)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) (PHASE3)
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NA)
- A Comparison of CoolStick With Ethyl Chloride for the Assessment of Light Touch
- Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer (PHASE2)
- 3 mL Inhaled Methoxyflurane for Intrauterine Device (IUD) Insertion (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chelen CI brief — competitive landscape report
- Chelen updates RSS · CI watch RSS